Studies on the Red Marrow Dosimetry in Radioimmunotherapy: An Experimental Investigation of Factors Influencing the Radiationinduced Myelotoxicity in Therapy with β-, Auger/Conversion Electron-, or α-Emitters

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages

  Behr, Thomas M ^a   Sgouros, George ^b   Stabin, Michael G ^c   Béhé, Martin ^a   Angerstein, Christa ^a   Blumenthal, Rosalyn D ^d   Apostolidis, Christos ^e   Molinet, Roger ^e   Sharkey, Robert M ^d   Koch, Lothar ^e   Goldenberg, David M ^d   Becker, Wolfgang ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^d GARDEN STATE CANCER CENTER   (United States)

^e JOINT RESEARCH CENTRE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; EDRECOLOMAB; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; INDIUM 111; IODINE 125; IODINE 131; MONOCLONAL ANTIBODY MN 14; RADIOISOTOPE; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW; BONE MARROW TOXICITY; CONFERENCE PAPER; CONTROLLED STUDY; DOSIMETRY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOBIOLOGY; RADIOIMMUNOTHERAPY; RADIOISOTOPE DISTRIBUTION;

ALPHA PARTICLES; ANIMALS; BETA RAYS; BONE MARROW; ELECTRONS; FEMALE; MICE; MICE, NUDE; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 0032697299     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Behr, T. M., Sharkey, R. M., Juweid, M. E., Dunn, R. M., Vagg, R. C., Ying, Z., Zhang, C. H., Swayne, L. C., Vardi, Y., Siegel, J. A., and Goldenberg, D. M. Phase I/II clinical radioimmunotherapy with an 131I-labeled anti-CEA murine IgG monoclonal antibody. J. Nucl. Med., 38. 858-870, 1997.
2. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., Matthews, D. C., Fisher, L. D., and Bernstein, I. D. Radiolabeledantibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329: 1219-1224, 1993.
3. Blumenthal, R. D., Sharkey, R. M., Forman, D., Wong, G., Hess, J., and Goldenberg, D. M. Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow trmasplantation. Exp. Hematol., 23: 1088-1097, 1995.
4. Harbert, J. C., Eckehnan, W. C., and Neumann, R. D. (eds.). Nuclear Medicine: Diagnosis and Therapy. New York: Thieme Medical Publishers, 1996.
5. Sgouros, G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J. Nucl. Med., 34: 689-694, 1993.
6. Behr, T. M., Holler, E., Gratz, S., Wörmann, B., Sharkey, R. M., Dunn, R. M., Hiddemann, W., Kolb, H. J., Goldenberg, D. M., and Becker, W. CD22 is a suitable target molecule for detection and highdose, myeloablative radioimmunotherapy with the monclonal antibody LL2 in acute lymphatic leukemia and Waldenström's macroglobulinemia. Tumor Targeting, 3: 32-40, 1998.
7. Hendry, J. H., and Lord, B. I. (eds.). Radiation Toxicology: Bone Marrow and Leukaemia. London: Taylor & Francis, 1995.
8. Behr, T. M., Sharkey, R. M., Juweid, M. E., Dunn, R. M., Vagg, R. C., Siegel, J. A., Goldenberg, D. M. Hematologic toxicity in the radioimmunotherapy of solid cancers with 131I-labeled anti-CEA NP-4 IgG1: dependence on red marrow dosimetry and pretreatment. Proceedings of the 6th International Radiopharmaceutical Dosimetry Symposium in Gatlinburg (TN) 1996, 1999, Vol. 1, pp. 113-126.
9. Muthuswamy, M. S., Roberson, P. L., and Buchsbaum, D. L. A mouse bone marrow dosimetry model. J. Nucl. Med., 39: 1243-1247, 1998.
10. Buchegger, F., Chalandon, Y., Pèlegrin, A., Hardman, N., and Mach, J. P. Bone marrow dosimetry in rats using direct tissue counting after injection of radio-iodinated intact monoclonal antibodies or (Fab’)2 fragments. J. Nucl. Med., 32: 1414-1421, 1991.
11. Larson, S. M., Raubitschek, A., Reynolds, J. C., Neumann, R. D., Hellstrom, K. E., Heltstrom, I., Colcher, D., Schlom, J., Glatstein, E., Carrasquitlo, J. A. Comparison of bone marrow dosimetry and toxic effect of high dose 131I-labeled monoclonal antibodies administered to man. Int. J. Rad. Appl. Instrnm. B, 16: 153-158, 1989.
12. Zanzonico, P., and Sgouros, G. Predicting myetotoxicity in radioimmunotherapy: what does dosimetry contribute? J. Nucl. Med., 38: 1753-1754, 1997.
13. Juweid, M., Sharkey, R. M., Siegel, J. A., Behr, T., and Goldenberg, D. M. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy in patients having non-Hodgkin's lymphoma (NHL) and diffuse bone marrow uptake. Cancer Res., 55 (Suppl.): 5827s-5831s, 1995.
14. Sgouros, G., Jureidini, I. M., Scott, A. M., Graham, M. C., Larson, S. M., and Scheinberg, D. A. Bone marrow dosimetry: regional variability of marrow-localizing antibody. J. Nucl. Med., 37: 695-698, 1996.
15. Siegel, J. A., Lee, R. E., Pawlyk, D. A., Horowitz, J. A., Sharkey, R. M., and Goldenberg, D. M. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Int. J. Rad. Appl. Instrum. B, 16: 553-559, 1989.
16. Behr, T. M., Sharkey, R. M., Sgouros, G., Blumenthal, R. D., Dunn, R. M., Kolbert, K., Griffiths, G. L., Siegel, J. A., Becket, W. S., and Goldenberg, D. M. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer (Phila.), 80: 2591-2610, 1997.
17. Behr, T. M., Memtsoudis, S., Sharkey, R. M., Blumenthal, R. D., Dunn, R. M., Gratz, S., Wieland, E., Nebendahl, K., Schmidberger, H., Goldenberg, D. M., and Becker, W. Experimental studies on the role of antibody fragments in cancer radioimmunotherapy: influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int. J. Cancer, 77: 787-795, 1998.
18. Hall, E. J. Radiobiology for the Radiologist. Philadelphia: J. B. Lippincott, 1994.
19. Walden, T. L., Jr., and Farzaneh, N. K. Biochemistry of Ionizing Radiation. New York: Raven Press, 1990.
20. Behr, T. M., Sgouros, G., Sharkey, R. M., Dunn, R. M., Blumenthal, R. D., Kolbert, K., Juweid, M. E., Siegel, J. A., and Goldenberg, D. M. 9OY dosimetry in the nude mouse: evaluation of three dosimetry models in relation to observed biological effects in radioimmunotherapy of human colon cancer xenografts. Proceedings of the 6th International Radiopharmaceutical Dosimetry Symposium in Gatlinburg (TN) 1996, 1999, Vol. 1, pp. 257-271.
21. Behr, T. M., Sgouros, G., Sharkey, R. M., Dunn, R. M., Blumenthal, R. D., Kolbert, K., Siegel, J. A., and Goldenberg, D. M. Y-90-dosimetry in nude mice requires accounting for cross-organ radiation: evaluation of three dosimetry models in relation to observed biological effects. J. Nucl. Med., 37: 102P, 1996.
22. Behr, T. M., Sgouros, G., Vougioukas, V., Memtsoudis, S., Gratz, S., Schmidberger, H., Goldenberg, D. M., and Becker, W. Therapeutic efficacy and dose-limiting toxicity of Auger-electron versus β emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125Iversus 131I-labeled CO17-1A in a human colorectal cancer model. Int. J. Cancer, 76: 738-748, 1998.
23. Hansen, H. J., Goldenberg, D. M., Newman, E. S., Grebenau, R., and Sharkey, R. M. Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. Cancer (Phila.), 71: 3478-3485, 1993.
24. Sharkey, R. M., Goldenberg, D. M., Murthy, S., Pinsky, H., Vagg, R., Pawlyk, D., Siegel, J. A., Wong, G. Y., Gascon, P., Izon, D. O., Vezza, M., Burger, K., Swayne, L. C., Pinsky, C. M., and Hansen, H. J. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer (Phila.), 71: 2082-2096, 1993.
25. Sharkey, R. M., Juweid, M., Shevitz, J., Behr, T., Dunn, R., Swayne, L. C., Wong, G. Y., Blumenthal, R. D., Griffiths, G. L., Siegel, J. A., Leung, S., Hansen, H. J., and Goldenberg, D. M. Evaluation of a CDR-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody in preclinical and clinical studies. Cancer Res., 55: 5935-5945, 1995.
26. Behr, T. M., Wulst, E., Radetzky, S., Blumenthal, R. D., Dunn, R. M., Gratz, S., Rave-Fräink, M., Schmidberger, H., Raue, F., and Becker, W. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res., 57:5309-5319, 1997.
27. Pawlak-Byczkowska, E. J., Hansen, H. J., Dion, A. S., and Goldenberg, D. M. Two new monoclonal antibodies reactive with human lymphoma. Cancer Res., 49: 4568-4577, 1989.
28. Goldenberg, D. M., Horowitz, J. A., Sharkey, R. M., Hall, T. C., Murthy, S., Goldenberg, H., Lee, R. E., Stein, R., Siegel, J. A., lzon, D. O., Burger, K., Swayne, L. C., Belisle, E., Hansen, H. J., and Pinsky, C. M. Targeting, dosimetry and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J. Clin. Oncol., 9: 548-564, 1991.
29. Juweid, M., Sharkey, R. M., Markowitz, A., Behr, T., Swayne, L. C., Hansen, H. J., Shevitz, J., Leung, S., Rubin, A. D., Herskovic, T., Hanley, D., and Goldenberg, D. M. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res., 55: 5899-5907, 1995.
30. McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., Jain, V., Ho, A. D., Lister, J., Wey, K., Shen, D., and Dallaire, B. K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol., 16: 2825-2833, 1998.
31. Behr, T. M., Wörmann, B., Gramatzki, M., Riggert, J., Gratz, S., Béhé, M., Griesinger, F., Sharkey, R. M., Kolb, H-J., Hiddemann, W., Goldenberg, D. M., and Becker, W. Low-versus high-dose radioimmnnotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B-cell-associated malignancies. Clin. Cancer Res., 5 (Suppl.): 3305s-3315s, 1999.
32. Brechbiel, M. W., Gansow, O. A., Achter, R. W., Schlom, J., Esteban, J. M., Simpson, D. E., Colcher, D. Synthesis of 1-(p-isothiocyanobenzyl) derivatives of DTPA and EDTA: antibody labeling and tumor imaging studies. Inorg. Chem., 25:2772-2781, 1986.
33. Behr, T. M., Béhé, M., Stabin, M. G., Wehrmann, E., Apostolidis, C., Molinet, R., Strutz, F., Fayyazi, A., Wieland, E., Gratz, S., Koch, L., Goldenberg, D. M., and Becker, W. High-linear energy transfer (LET) α versus low-LET β emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi-versus 9OY-labeled CO17-1A Fab' fragments in a human colonic cancer model. Cancer Res., 59: 2635-2643, 1999.
34. Furhang, E. E., Sgouros, G., and Chui, C. S. Radionuclide photon dose kernels for internal emitter dosimetry. Med. Phys., 23: 759-764, 1996.
35. Goddu, S. M., Howell, R. W., and Rao, D. V. Generalized approach to absorbed dose calculations for dynamic tumor and organ masses. J. Nucl. Med., 36: 1923-1927, 1995.
36. Goddu, S. M., Howell, R. W., and Rao, D. V. Cellular dosimetry: absorbed fractions for monoenergetic electron and αparticle sources and S-values for radionuclides uniformly distributed in different cell compartments. J. Nucl. Med., 35: 303-316, 1994.
37. Yoriyaz, H., and Stabin, M. Electron and photon transport in a model of a 30g mouse. J. Nucl. Med., 38: 228P, 1997.
38. Bowalekar, S. K. Statistics in medical research: IV. Sampling distribution, statistical testing of hypothesis and Student's t-test. J. Postgrad. Med. 40: 46-51, 1994.
39. Shadduck, R. K., Waheed, A., and Wing, E. J. Demonstration of a blood-bone marrow barrier to macrophage colony-stimulating factor. Blood, 73: 68-73, 1989.
40. Wu, C., Kobayashi, H., Sun, B., Yoo, T. M., Paik, C. H., Gansow, O. A., Carrasquillo, J. A., Pastan, I., Brechbiel, M. W. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg Med Chem 5: 1925-1934, 1997.
41. Glasgow, G. P., Beetham, K. L., and Mill, W. B. Dose rate effects on the survival of normal hematopoietic stem cells of BALB/c mice. Int. J. Radiat. Oncol. Biol. Phys., 9: 557-563, 1983.
42. Tarbell, N. J., Amato, D. A., Down, J. D., Mauch, P., and Hellman, S. Fractionation and dose rate effects in mice: a model for bone marrow transplantation in man. Int. J. Radiat. Oncol. Biol. Phys., 13: 1065-1069, 1987.
43. FitzGerald, T. J., Santucci, M. A., Harigaya, K., Woda, B., McKenna, M., Sakakeeny, M. A., Pierce, J. H., Kase, K., Holland, C. A., and Greenberger, J. S. Radiosensitivity of permanent human bone marrow stromal cellines: effects of dose rate. Int. J. Radiat. Oncol. Biol. Phys., 15: 1153-1159, 1988.
44. Down, J. D., Tarbell, N. J., Thames, H. D., and Mauch, P. M. Syngeneic and allogeneic bone marrow engraftment after total body irradiation: dependence on dose, dose rate, and fi'actionation. Blood, 77: 661-669, 1991.
45. van Os, R., Thames, H. D., Konings, A. W., and Down, J. D. Radiation dose-fractionation and dose-rate relationships for long-term repopulating hemopoietic stem cells in a murine bone marrow transplant model. Radiat. Res., 136:118-125, 1993.
46. Yamamoto, O., Yokoro, K., Seyama, T., Kinomura, A., and Nomura, T. HTO oral administration in mice. I. Threshold dose rate for haematopoietic death. Int. J. Radiat. Biol., 57: 543-549, 1990.
47. Howell, R. W., Goddu, S. M., and Rao, D. V. Design and performance characteristics of an experimental cesium-137 irradiator to simulate internal radionuclide dose rate patterns. J. Nucl. Med., 38: 727-731, 1997.
48. Goddu, S. M., Howell, R. W., and Rao, D. V. Biologic dosimetry of bone marrow: implications for radionuclide therapy. Tumor Targeting, 2: 146, 1996.
49. Mackova, N., and Praslicka, M. Recovery of hematopoiesis in bone marrow of mice after continuous irradiation with dose rate 4.8 Gy/day. Neoplasma, 28: 79-86, 1981.
50. Howell, R. W., Azure, M. T., Narra, V. R., Rao, D. V. Relative biological effectiveness of α-emitters in vivo at low doses. Radiat. Res., 137: 352-360, 1994.
51. Howell, R. W., Goddu, S. M., Narra, V. R., Fisher, D. R., Schenter, R. E., and Rao, D. V. Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: relative biological effectiveness of α-particle emitters in vivo. Radiat. Res., 147: 342-348, 1997.
52. Charlton, D. E., Utteridge, T. D., and Allen, B. J. Theoretical treatment of human haemopoietic stem cell survival following irradiation by α particles. Int. J. Radiat. Biol., 74: 111-118, 1998.
53. Macklis, R. M., Beresford, B. A., Lin, J. Y., Atcher, R. W., and Humm, J. L. Murine hematopoietic ablation by α-particle-emitting radiopharmaceuticals: a potential preparative regimen for bone marrow transplantation? Int. J. Oncol., 2: 711-715, 1993.
54. Jurcic, J. G., McDevitt, M. R., Sgouros, G., Ballangrud, Å., Finn, R. D., Ma, D., Geerlings, M. W., Humm, J. L., Brechbiel, M. W., Molinet, R., Apostolidis, C., Larson, S. M., and Scheinberg, D. A. Targeted α-particle therapy for myeloid leukemias: a Phase I trial of bismuth-213-HuM195 (anti-CD33). Cancer Biotherapy Radiopharm., 13: 317, 1998.